MedTrace Logo

PCP in Immunocompromised Population in Southern China

NCT05605145 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2022-11-04

No results posted yet for this study

Summary

To evaluate the sensitivity and specificity of the combined detection system for the diagnosis of pneumocystis infection in immunocompromised population in Southern China.

Conditions

  • Immunocompromised Patients
  • Pneumocystis Pneumonia
  • Diagnosis
  • Polymerase Chain Reaction

Interventions

DIAGNOSTIC_TEST

PCR was used to detect pneumocystis in respiratory specimens

Respiratory tract specimens such as alveolar lavage fluid, sputum and throat swabs were collected from all patients who met the enrollment conditions of this study. qPCR and/or mNGS were used to detect pneumocystis in respiratory specimens.

Sponsors & Collaborators

  • People's Hospital of Guangxi Zhuang Autonomous Region

    collaborator OTHER

  • The Fourth People's Hospital of Nanning

    collaborator OTHER

  • Chest Hospital of Guangxi Zhuang Autonomous Region

    collaborator UNKNOWN

  • People's Hospital of Baise

    collaborator UNKNOWN

  • LiuZhou People's Hospital

    collaborator OTHER

  • The second Nanning People's Hospital

    collaborator UNKNOWN

  • The People's Hospital of Wuzhou

    collaborator UNKNOWN

  • Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region

    collaborator OTHER

  • Second Affiliated Hospital of Guangzhou Medical University

    collaborator OTHER

  • 923rd Hospital of the People's Liberation Army

    collaborator UNKNOWN

  • First Affiliated Hospital of Guangxi Medical University

    lead OTHER

Principal Investigators

  • Cunwei Cao, MD · First Affiliated Hospital of Guangxi Medical University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-12
Primary Completion
2022-12-31
Completion
2023-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05605145 on ClinicalTrials.gov